Analytical Data
-
Gene name
CHN1
- Application
-
Alternative Names
CHN; DURS2; RhoGAP2; ARHGAP2; NC; N-Chimerin; Chimaerin; A-chimaerin; Alpha-chimerin; GTPase-Activating Protein,Rho 2; Duane Retraction Syndrome 2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P15882
-
Expression Region
Ala2~Leu259
-
Molecular Weight
34kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of CHN1 (Choline transporter-like protein 1) recombinant protein has garnered significant attention due to its essential role in neurotransmission and cellular signaling. CHN1 is crucial for the uptake of choline, a precursor for the synthesis of acetylcholine, an important neurotransmitter involved in various cognitive and motor functions. Dysregulation of choline transport is implicated in several neurological disorders, including Alzheimer's disease, schizophrenia, and attention-deficit hyperactivity disorder (ADHD). The generation of CHN1 recombinant protein enables researchers to investigate its structural and functional properties in detail, paving the way for understanding its mechanisms of action and interactions with other cellular components. Moreover, studying CHN1 recombinant protein facilitates the development of potential therapeutic strategies targeting choline transport, which could lead to novel treatments for disorders associated with impaired neurotransmitter regulation. By utilizing techniques such as heterologous expression systems, protein purification, and functional assays, researchers aim to elucidate the biophysical characteristics of CHN1 and its role in maintaining cholinergic signaling. As the field continues to advance, the insights gained from CHN1 recombinant protein studies could significantly impact the understanding of mental health and neurodegenerative diseases, highlighting the importance of choline transport in overall brain function.
